Kostas Biliouris
Stock Analyst at BMO Capital
(1.12)
# 1,985
Out of 4,412 analysts
35
Total ratings
31.03%
Success rate
-10.57%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $15 | $9.16 | +63.76% | 4 | Apr 1, 2024 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $70 → $63 | $23.93 | +163.27% | 3 | Apr 1, 2024 | |
| BEAM Beam Therapeutics | Maintains: Outperform | $57 | $21.22 | +168.61% | 3 | Mar 27, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $234 | $143.95 | +62.56% | 3 | Mar 27, 2024 | |
| KRRO Korro Bio | Reiterates: Outperform | $120 | $56.79 | +111.30% | 2 | Mar 26, 2024 | |
| MGX Metagenomi | Initiates: Outperform | $22 | $7.02 | +213.39% | 1 | Mar 5, 2024 | |
| SRPT Sarepta Therapeutics | Initiates: Outperform | $170 | $126.66 | +34.22% | 1 | Jan 31, 2024 | |
| BBIO BridgeBio Pharma | Initiates: Market Perform | $37 | $25.62 | +44.42% | 1 | Jan 31, 2024 | |
| SLN Silence Therapeutics | Initiates: Outperform | $67 | $21.86 | +206.50% | 1 | Jan 31, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $64 → $62 | $21.40 | +189.72% | 4 | Nov 10, 2023 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $102 → $100 | $80.76 | +23.82% | 4 | Nov 3, 2023 | |
| PRME Prime Medicine | Initiates: Outperform | $19 | $4.92 | +286.18% | 1 | Oct 9, 2023 | |
| LEGN Legend Biotech | Maintains: Outperform | $79 → $90 | $43.74 | +105.76% | 2 | Apr 25, 2023 | |
| DTIL Precision BioSciences | Downgrades: Market Perform | $210 → $120 | $10.41 | +1,052.74% | 2 | Mar 14, 2023 | |
| VERV Verve Therapeutics | Maintains: Outperform | $48 → $62 | $6.01 | +931.61% | 2 | Jul 18, 2022 | |
| CRSP CRISPR Therapeutics AG | Initiates: Outperform | $98 | $52.99 | +84.94% | 1 | Jun 17, 2022 |
Centessa Pharmaceuticals
Apr 1, 2024
Maintains: Outperform
Price Target: $15
Current: $9.16
Upside: +63.76%
4D Molecular Therapeutics
Apr 1, 2024
Maintains: Outperform
Price Target: $70 → $63
Current: $23.93
Upside: +163.27%
Beam Therapeutics
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $21.22
Upside: +168.61%
Alnylam Pharmaceuticals
Mar 27, 2024
Maintains: Outperform
Price Target: $234
Current: $143.95
Upside: +62.56%
Korro Bio
Mar 26, 2024
Reiterates: Outperform
Price Target: $120
Current: $56.79
Upside: +111.30%
Metagenomi
Mar 5, 2024
Initiates: Outperform
Price Target: $22
Current: $7.02
Upside: +213.39%
Sarepta Therapeutics
Jan 31, 2024
Initiates: Outperform
Price Target: $170
Current: $126.66
Upside: +34.22%
BridgeBio Pharma
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $25.62
Upside: +44.42%
Silence Therapeutics
Jan 31, 2024
Initiates: Outperform
Price Target: $67
Current: $21.86
Upside: +206.50%
Intellia Therapeutics
Nov 10, 2023
Maintains: Outperform
Price Target: $64 → $62
Current: $21.40
Upside: +189.72%
BioMarin Pharmaceutical
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $80.76
Upside: +23.82%
Prime Medicine
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $4.92
Upside: +286.18%
Legend Biotech
Apr 25, 2023
Maintains: Outperform
Price Target: $79 → $90
Current: $43.74
Upside: +105.76%
Precision BioSciences
Mar 14, 2023
Downgrades: Market Perform
Price Target: $210 → $120
Current: $10.41
Upside: +1,052.74%
Verve Therapeutics
Jul 18, 2022
Maintains: Outperform
Price Target: $48 → $62
Current: $6.01
Upside: +931.61%
CRISPR Therapeutics AG
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $52.99
Upside: +84.94%